Related Experiment Video
Updated: May 10, 2026

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
Published on: June 25, 2019
Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia
Anne Louise Oaklander1, Zeva Daniela Herzog, Heather M Downs
1Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Department of Pathology (Neuropathology), Massachusetts General Hospital, Boston, MA, USA.
Abstract:
Fibromyalgia is a common, disabling syndrome that includes chronic widespread pain plus diverse additional symptoms. No specific objective abnormalities have been identified, which precludes definitive testing, disease-modifying treatments, and identification of causes. In contrast, small-fiber polyneuropathy (SFPN), despite causing similar symptoms, is definitionally a disease caused by the dysfunction and degeneration of peripheral small-fiber neurons. SFPN has established causes, some diagnosable and definitively treatable, eg, diabetes. To evaluate the hypothesis that some patients labeled as having fibromyalgia have unrecognized SFPN that is causing their illness symptoms, we analyzed SFPN-associated symptoms, neurological examinations, and pathological and physiological markers in 27 patients with fibromyalgia and in 30 matched normal controls. Patients with fibromyalgia had to satisfy the 2010 American College of Rheumatology criteria plus present evidence of a physician's actual diagnosis of fibromyalgia. The study's instruments comprised the Michigan Neuropathy Screening Instrument (MNSI), the Utah Early Neuropathy Scale (UENS), distal-leg neurodiagnostic skin biopsies, plus autonomic-function testing (AFT). We found that 41% of skin biopsies from subjects with fibromyalgia vs 3% of biopsies from control subjects were diagnostic for SFPN, and MNSI and UENS scores were higher in patients with fibromyalgia than in control subjects (all P ≤ 0.001). Abnormal AFTs were equally prevalent, suggesting that fibromyalgia-associated SFPN is primarily somatic. Blood tests from subjects with fibromyalgia and SFPN-diagnostic skin biopsies provided insights into causes. All glucose tolerance tests were normal, but 8 subjects had dysimmune markers, 2 had hepatitis C serologies, and 1 family had apparent genetic causality. These findings suggest that some patients with chronic pain labeled as fibromyalgia have unrecognized SFPN, a distinct disease that can be tested for objectively and sometimes treated definitively.
Insights
Many fibromyalgia patients may have undiagnosed small-fiber polyneuropathy (SFPN). This study found objective evidence of SFPN in 41% of fibromyalgia patients, suggesting a distinct, treatable cause for their chronic pain.
Area of Science:
- Neurology
- Rheumatology
- Pathology
Background:
- Fibromyalgia is a disabling syndrome with chronic widespread pain and diverse symptoms.
- Lack of objective abnormalities hinders diagnosis, treatment, and cause identification for fibromyalgia.
- Small-fiber polyneuropathy (SFPN) causes similar symptoms and is a distinct disease of small-fiber neurons with identifiable causes.
Purpose of the Study:
- To test the hypothesis that some fibromyalgia patients have unrecognized SFPN.
- To identify objective markers for SFPN in fibromyalgia patients.
Main Methods:
- Analyzed SFPN symptoms, neurological exams, and markers in 27 fibromyalgia patients and 30 controls.
- Utilized Michigan Neuropathy Screening Instrument (MNSI), Utah Early Neuropathy Scale (UENS), skin biopsies, and autonomic-function testing (AFT).
Main Results:
- 41% of fibromyalgia patients showed SFPN-diagnostic skin biopsies, versus 3% in controls.
- Higher MNSI and UENS scores in fibromyalgia patients (P ≤ 0.001).
- Abnormal AFTs were equally prevalent, indicating primarily somatic SFPN.
Conclusions:
- A significant portion of fibromyalgia patients may have undiagnosed SFPN.
- SFPN is an objective, distinct disease that can be diagnosed and sometimes treated.
- Identified potential causes including dysimmune and genetic factors in some patients.
More Related Videos
08:33A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
Published on: January 5, 2024
09:39Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
Published on: February 13, 2018
Related Concept Videos
Local Anesthetics: Differential Sensitivity of Nerve Fibers
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Myasthenia Gravis ll: Pathophysiology
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...